Actinomycin D (Dactinomycin)

Catalog No.S8964 Batch:S896401

Print

Technical Data

Formula

C62H86N12O16
Molecular Weight 1255.42 CAS No. 50-76-0
Solubility (25°C)* In vitro DMSO 100 mg/mL (79.65 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Actinomycin D (Dactinomycin, Act D, RASP-101) is a significant polypeptide antibiotic isolated from soil bacteria of the genus Streptomyces. Actinomycin D (Dactinomycin) inhibits DNA repair and rests the cell cycle at G1 phase with IC50 of 0.42 μM and 0.4 nM, respectively. Actinomycin D is an RNA and protein synthesis inhibitor that can suppress bacterial protein synthesis. Actinomycin D is an autophagy activator, induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing.
Targets
autophagy [3] cell cycle [1]
(Cell-based assay)		 DNA repair [2]
(Cell-free assay)
0.4 nM 0.42 μM
In vitro

Actinomycin D (Dactinomycin) markedly reduces the SMC proliferation via the inhibition of BrdU incorporation at 80 nM. This is further supported by the G1-phase arrest using a flowcytometric analysis. The protein expression levels of proliferating cell nuclear antigen (PCNA), focal adhesion kinase (FAK), and Raf are all suppressed by this compound. Extracellular signalregulated kinases (Erk) involved in cell-cycle arrest are found to be increased by it.
In vivo

Actinomycin D (Dactinomycin) targets survival proteins TOSO, BCL2 and MCL1 and is active in two different mouse models that are characterized by either unmutated B-cell receptor or inactive p53 function, both of which are known negative prognostic factors in CLL.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    A10 cells (Vascular SMC)

  • Concentrations

    80 nM, 800 nM, 8 μM

  • Incubation Time

    18-24 h

  • Method

    Cultured SMC are starved for 24 h followed by incubation with various doses of actinomycin D (dactinomycin) at 37℃. Drug treatment is carried out for 18-24 h. Since it is dissolved in 0.1% DMSO, a vehicle control containing DMSO is also included.
Animal Study:

[3]
  • Animal Models

    C57BL/6 wild-type mice engrafted with tumor cells from Em-TCL-1 transgenic mice

  • Dosages

    0.06 mg/kg

  • Administration

    IP

References

  • https://pubmed.ncbi.nlm.nih.gov/15959627/
  • https://pubmed.ncbi.nlm.nih.gov/9450493/
  • https://pubmed.ncbi.nlm.nih.gov/22743622/

Selleck's Actinomycin D (Dactinomycin) Has Been Cited by 159 Publications

Targeting NSUN2-Mediated m5C Modification Attenuates Chondrocyte Senescence and NLRP3 Activation in Osteoarthritis [ Adv Sci (Weinh), 2026, e76370] PubMed: 42405873
SERBP1 is required for efficient HR repair and cisplatin chemoresistance in lung adenocarcinoma [ Cell Death Discov, 2026, 12(1)162] PubMed: 41856985
ADAMDEC1-driven CCL2-CCR2-PD-1 axis in esophageal squamous cell carcinoma: a dual threat of O-GlcNAcylation and m6A methylation in neoadjuvant therapy resistance and immune evasion [ Cell Oncol (Dordr), 2026, 49(2)68] PubMed: 41944985
SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma [ Cancer Sci, 2026, 10.1111/cas.70353] PubMed: 41776708
Single-cell transcriptomic analysis reveals that the circRNA circGCLM promotes tumorigenesis and confers cisplatin resistance in NSCLC through the miR-505-3p/ERBB4 axis [ Transl Oncol, 2026, 67:102759] PubMed: 41950669
A new mechanism regulating microglial NLRP3 inflammasome: FMR1 mediates NLRP3 mRNA stability [ PLoS One, 2026, 21(2):e0341867] PubMed: 41719238
IGF2BP3 promotes gastric cancer progression by inhibiting ferroptosis through ETV4-mediated regulation of GCH1 [ Cancer Biol Ther, 2026, 27(1):2664967] PubMed: 42068022
Phosphoglycerate dehydrogenase stabilizes protein kinase C delta type mRNA to promote hepatocellular carcinoma progression [ Signal Transduct Target Ther, 2025, 10(1):236] PubMed: 40681503
Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancer [ Mol Cancer, 2025, 24(1):217] PubMed: 40819058
RNA m6A regulates the transcription and heterochromatin state of retrotransposons in Arabidopsis [ Nat Plants, 2025, 11(11):2300-2318] PubMed: 41136675

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Jump to: